Patent · US Active

Preparation of anhydrous and hydrated polymorphs 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-YL)-1H-benzimidazol-2-YL]-1H-quinolin-2-one-lactic acid salt

US8987448B2 · kind B2 · utility

0Cited by

2References

14Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Arnaud GRANDEURY · Helfrantzkirch, FR
Christian RIEGERT · Sierentz, FR
Andreas Schreiner · Rheinfelden, CH

Key dates

Filing date	Mar 25, 2011
Grant date	Mar 24, 2015
Priority date	—
Expiry date	Aug 27, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present technology provides methods of making anhydrous crystalline Form II and monohydrate crystalline Form B of the lactic acid salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.